Schedule of Noncontrolling Interest of Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Noncontrolling Interest [Abstract]
NCI – equity – December 31, 2022	$ 20,615
Net loss attributable to NCI	(4,283)	$ (2,761)
Impact of subsidiary equity transactions	(1,189)
Lucid Diagnostics Inc. proceeds from issuance of preferred stock	13,625
Lucid Diagnostics Inc. proceeds from At-The-Market Facilities, net of deferred financing charges	284
Lucid Diagnostics Inc. issuance of common stock for settlement of APA-RDx installment and termination payment	713
Lucid Diagnostics Inc. Employee Stock Purchase Plan Purchase	276
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan	2,817
Stock-based compensation expense - Veris Health Inc. 2021 Equity Plan	3
NCI – equity – March 31, 2023	$ 32,861